There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KemPharm (NASDAQ:KMPH) and MyoKardia Inc (NASDAQ:MYOK) with bullish sentiments.
KemPharm (KMPH)
In a report released yesterday, Dewey Steadman from Canaccord Genuity maintained a Buy rating on KemPharm, with a price target of $11. The company’s shares opened today at $4.80.
Steadman commented:
“We hosted KemPharm CEO Travis Mickle at our annual Conference this afternoon. KemPharm uses its proprietary prodrug technology to enhance small molecule drug release characteristics and has secured approval for Apadaz, an immediate-release hydrocodone prodrug, validating the company’s tech platform. KemPharm’s lead programs are in adult and pediatric ADHD, and we expect incremental data for the KP415 (peds) and KP484 (adult) programs over the coming quarters.”
According to TipRanks.com, Steadman is a 3-star analyst with an average return of 4.2% and a 39.2% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.
KemPharm has an analyst consensus of Strong Buy, with a price target consensus of $12.13, which is a 152.7% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
MyoKardia Inc (MYOK)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on MyoKardia Inc yesterday and set a price target of $73. The company’s shares opened today at $58.65, close to its 52-week high of $63.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.3% and a 55.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MyoKardia Inc with a $73.67 average price target, representing a 25.6% upside. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $77 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
